GlobeNewsWire
13 Jun 2026, 13:00 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Mitapivat demonstrated a statistically significant improvement in the primary endpoint of hemoglobin response compared to placebo in the RISE UP Phase 3 trial. — Meeting a primary endpoint in a Phase 3 trial is a critical milestone for regulatory approval and commercial viability.
+0.60New analyses show mitapivat achieved a 41.1% relative reduction in the proportion of patients requiring blood transfusions and a 55.9% reduction in average units transfused. — Reducing transfusion burden provides a strong clinical value proposition that enhances the drug's competitive positioning.
+0.50The trial failed to reach statistical significance for the primary endpoint of reducing the annualized rate of sickle cell pain crises (SCPCs) across the general study population. — Failure to meet a primary clinical endpoint regarding pain crises introduces regulatory risk and may limit the label's breadth.
-0.40Continue reading
6 related stories
Search tags
A post-hoc analysis revealed that patients who responded to hemoglobin increases saw a 26% reduction in SCPCs and 34% fewer related hospitalizations. — While positive, post-hoc analyses are less weighted by regulators than primary endpoints, though they suggest a path for patient stratification.
+0.30Which stocks this story touches
The company presented positive Phase 3 trial results for mitapivat, showing significant improvements in hemoglobin response and reduction in transfusion burden.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
